Phase IIa Data Summary: Oral Salmon Calcitonin
Dose response was demonstrated
Significant reduction in bone markers from baseline levels
- 2 of 5 doses (p = 0.002 and p=.016 )
No serious adverse events associated with the EMISPHERE® delivery agent or with the calcitonin
Summary: Represents the longest time period over which our technology has been administered, further demonstrating the safety profile of the eligen™
Additional manufacturing, formulations and packaging work done by NVS